Olmeamlo Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine, hydrochlorothiazide, the active ingredient in Olmeamlo Hct, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, often when single‑agent therapy does not provide adequate blood pressure control.

GNH USA supplies Olmeamlo Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmeamlo Hct is indicated for hypertension, a condition characterized by elevated arterial pressure, and works within the cardiovascular system to lower blood pressure. - Hypertension: helps achieve target blood pressure levels and reduces cardiovascular risk. - Hypertension resistant to monotherapy: provides additional blood pressure reduction when a single agent is insufficient. - Hypertension with fluid retention: combines a diuretic to address volume overload while lowering pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness: especially after standing. - Flushing: transient warmth and redness. - Fatigue: general tiredness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte imbalance: significant changes in potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, consider the following safety measures: - Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially with diuretic use. - Cardiovascular status: evaluate for heart failure or recent myocardial infarction. - Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional. - Drug hypersensitivity: review patient history for allergies to any component. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmeamlo Hct may interact with several drug classes; monitoring and dose adjustments are often required.

Major Interactions (Avoid): - Aliskiren: concurrent use with ACE inhibitors or ARBs can increase risk of renal impairment. - Potassium‑saving diuretics or supplements: may cause hyperkalaemia. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): can raise amlodipine concentrations. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.